Close X
Attorney Spotlight

How does Jessie Zeigler anticipate the intersection of privacy and smart technology will impact the future of litigation? Find out more>


Close X


Search our Experience

Experience Spotlight

Primary Care Providers Win Challenge of CMS Interpretation of Enhanced Payment Law

With the help and support of the Tennessee Medical Association, 21 Tennessee physicians of underserved communities joined together and retained Bass, Berry & Sims to file suit against the Centers for Medicare & Medicaid Services to stop improper collection efforts. Our team, led by David King, was successful in halting efforts to recoup TennCare payments that were used legitimately to expand services in communities that needed them. Read more

Tennessee Medical Association & Bass, Berry & Sims

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Healthcare Private Equity Compliance Checklist

The complex and ever-changing healthcare regulatory and enforcement environment, including increased focus on the role of private equity firms in their portfolio companies, make compliance a top priority for private equity firms investing in healthcare companies. The best way to limit your exposure as a private equity firm is to avoid a compliance misstep in the first place. Additionally, an effective and robust compliance program for your portfolio healthcare company makes it much more attractive to potential buyers and helps you avoid an unexpected and costly investigation or valuation hit down the road. Download the Healthcare Private Equity Compliance Checklist to assess whether your portfolio company's compliance program is up-to-date.

Click here to download the checklist.

Senior DOJ Official Comments on FCPA Enforcement Trends and Anti-Corruption Compliance Programs


April 28, 2015

On April 27, 2015, at ACI's 9th Annual Advanced Forum on FCPA & the Life Sciences Industry, Daniel Kahn, Assistant Chief of the FCPA Unit at the U.S. Department of Justice's ("DOJ") Fraud Section, offered remarks on U.S. Foreign Corrupt Practices Act ("FCPA") enforcement trends, the value of an anti-corruption compliance program and on various components of such compliance programs. The remarks were largely in response to specific questions from the audience during an hour-long Q&A-style panel.

FCPA Enforcement Trends

Kahn made specific mention of three often-discussed trends:

  1. DOJ will continue to prosecute individuals for FCPA violations;
  2. DOJ will continue to reward voluntary self-disclosure and cooperation; and
  3. DOJ will continue to look for opportunities to cooperate and coordinate with global enforcement authorities.

Speaking specifically to the last trend, Kahn stated: "We do have a relationship with China and are working that relationship just as we are with any other country."

Kahn additionally touched on the distinction between cooperating and coordinating with a foreign enforcement agency. Regarding the latter, Kahn noted that DOJ often tries to coordinate foreign resolutions and give credit for resolutions a company enters into with another country. This is distinct from and in addition to cooperating with foreign enforcement agencies. Kahn offered the Siemens and ABM resolutions as examples of such coordination and noted that credit is more likely to happen when a company makes a voluntary disclosure.

Anti-Corruption Compliance Programs

As has become common refrain, Kahn emphasized that compliance programs are the best defense for preventing potential issues. He reiterated that such programs are one of the many factors DOJ considers when deciding whether to bring an FCPA enforcement action.

Kahn also touched on several specific components of an effective anti-corruption compliance program:

  1. Incentives: The need for employee "incentives" for compliant behavior was one of the first components Kahn discussed. He said that it was important for a company to link compliance to an individual’s performance by, for example, tying a bonus to compliance with company policies and training requirements.
  2. Gifts, Travel and Entertainment: When asked, Kahn stated that he believes companies should focus on gifts, travel and entertainment for several reasons, not just to prevent FCPA violations. On the FCPA-front, Kahn noted that a survey of DOJ enforcement actions would suggest a focus on "systemic" gifts and entertainment violations, which is distinct from the isolated, one-off meal or other entertainment activity.
  3. Third Parties: When speaking of third parties, Kahn noted there is no one type of third-party agent that a company should be cautious of; rather, the third parties considered "high risk" should be identified through a risk assessment process. Contractual and other third-party safeguards, while beneficial, lack teeth if not properly enforced. Kahn offered third-party audit rights and the need to actually exercise those rights as an example of the foregoing.
  4. Transactional Due Diligence: In the M&A context, Kahn reiterated that DOJ expects companies to "reasonably assess" a target company prior to an acquisition. Kahn also reminded the audience that if the target company was not subject to the FCPA's jurisdiction prior to the acquisition and no post-acquisition violations occur, then there will be no successor liability for pre-acquisition conduct.

While not groundbreaking, Kahn reemphasized that anti-corruption enforcement by U.S. and global enforcement agencies continues. Likewise, Kahn's statements demonstrate that DOJ gives corporate compliance programs a hard look when determining whether to exercise its discretion to bring a case and, if an action is brought, in the negotiation of the ultimate resolution. Keeping this in mind, every company should assess – and reassess – its anti-corruption compliance program and ensure that such programs are tailored to the needs of the organization and appropriately account for a company's unique risk landscape.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.